Online programs offering ketamine lozenges or tablets for depression and anxiety at home have grown quickly. Some people describe real relief. But the FDA has warned about the risks of compounded ketamine used outside a medical setting, and at-home programs work very differently from the FDA-approved esketamine treatment given in clinics. If you are considering one, understand those differences first.
Key Takeaways
- Ketamine is FDA-approved only as an injectable anesthetic; it is not FDA-approved for any psychiatric condition.
- In October 2023 the FDA warned about compounded ketamine products, including those sold through telemedicine for at-home use, citing risks like sedation, dissociation, slowed breathing, rising blood pressure and misuse.
- Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression, but only under a REMS program: it is given in certified healthcare settings with at least two hours of monitoring.
- Ketamine is a Schedule III controlled substance; current federal telehealth prescribing flexibilities run through December 31, 2026.
- If you try any ketamine treatment, insist on thorough screening, a sober monitor, clear dosing, and access to a clinician; do not combine it with alcohol or sedatives.
Where ketamine stands with the FDA
Ketamine has been used as an anesthetic for decades. Interest in its fast-acting antidepressant effects led to research and to off-label treatment at IV infusion clinics, and later to online programs shipping compounded oral or sublingual ketamine for home use.
The FDA's position is clear: ketamine is approved only as an injection for anesthesia. The agency has not approved it, or found it safe and effective, for depression, anxiety, PTSD or any other psychiatric disorder. Compounded ketamine products, which are what most at-home programs use, are not FDA-approved and have not been evaluated for safety, effectiveness or quality.
What the FDA warned about
In October 2023 the FDA issued a warning to patients and healthcare providers about compounded ketamine. Among its points:
- Risks include sedation, dissociation, increases in blood pressure, slowed breathing, abuse and misuse, psychiatric events, and bladder and urinary problems.
- At-home use adds risk because no healthcare provider is present to monitor for sedation, dissociation or changes in vital signs.
- People getting compounded ketamine through telemedicine may not receive full information about the risks.
- The FDA described a report of a patient who experienced slowed breathing after taking compounded oral ketamine at home, with a blood ketamine level about twice what is typical for anesthesia.
- The agency said there is no evidence that compounded ketamine is safer, more effective or faster-acting than FDA-approved treatments.
The FDA had earlier, in 2022, issued a compounding risk alert about compounded ketamine nasal spray.
How Spravato is different
Esketamine, a closely related molecule, is FDA-approved as Spravato nasal spray for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behaviour. It is approved with strict safety controls.
| At-home compounded ketamine | Spravato (esketamine) | |
|---|---|---|
| FDA approval for depression | No | Yes, for specific indications |
| Product oversight | Compounded; not FDA-reviewed | Manufactured to FDA-approved standards |
| Where it is taken | At home | Certified healthcare setting only |
| Monitoring after a dose | Typically none by a clinician on site | At least two hours by a healthcare provider under the REMS program |
| Driving | Program rules vary | Not until the next day after a restful sleep, per labeling |
| Insurance | Usually cash-pay | Often covered with prior authorization |
Spravato's REMS, a Risk Evaluation and Mitigation Strategy, exists precisely because of sedation, dissociation and misuse risks. The FDA noted that compounded ketamine is not part of any REMS. Some telehealth psychiatry practices can evaluate you and refer you to a certified Spravato treatment center.
The telehealth prescribing rules
Ketamine is a Schedule III controlled substance. Since 2020, temporary federal flexibilities have allowed clinicians to prescribe controlled substances by telemedicine without a prior in-person visit. The DEA and HHS most recently extended those flexibilities through December 31, 2026. What happens after that depends on future rulemaking, and states can add their own requirements. Our explainer on telehealth and controlled substances covers the framework.
Who should not use at-home ketamine
Responsible programs screen people out who are at higher risk. Situations that generally call for caution or exclusion include:
- History of psychosis, schizophrenia, or bipolar mania
- Current or past substance use disorder, especially involving ketamine, alcohol or sedatives
- Uncontrolled high blood pressure, heart disease, or history of stroke or aneurysm
- Pregnancy or breastfeeding
- Living alone without anyone available to monitor during and after a session
- Taking benzodiazepines, opioids or other sedatives
If an intake does not ask about these, that is a warning sign. See seven signs of a telehealth pill mill.
Questions to ask any ketamine program
- Who evaluates me, and what is their licence and specialty? Is there a psychiatric evaluation?
- What exactly is the product, who compounds it, and what is the dose per unit?
- Do you require a sober adult to be present during and after each session?
- How do you monitor blood pressure, side effects and mood between sessions?
- What happens if I have a bad reaction or worsening depression? Who do I call, and when are they available?
- How many sessions are planned, and how do you decide whether to continue?
- Can you refer me to Spravato or in-person care if that is a better fit?
If you do proceed: safety basics
- Never combine ketamine with alcohol, benzodiazepines, opioids or other sedatives.
- Have a sober adult present, sit or lie down in a safe space, and do not drive or operate machinery for the rest of the day.
- Take only the dose prescribed, never extra, and store the medicine securely away from others.
- Report urinary pain, blood in urine, or frequent urination, which can signal bladder problems.
- Report worsening mood, new suicidal thoughts, or confusion immediately.
- Report side effects to FDA MedWatch as well as to the program.
Other evidence-based paths
For depression that has not responded to a first treatment, options with stronger evidence and oversight include switching or adding antidepressants, evidence-based psychotherapy, Spravato in a certified clinic, transcranial magnetic stimulation, and in some cases electroconvulsive therapy. Telepsychiatry can help you work through these; see how telepsychiatry works and online psychiatry vs therapy.
Frequently Asked Questions
Is at-home ketamine FDA-approved?
No. Ketamine is FDA-approved only as an injectable anesthetic. Compounded ketamine sold for at-home psychiatric use is not FDA-approved, and the FDA has warned about its risks.
What is the difference between ketamine and Spravato?
Spravato is esketamine nasal spray, FDA-approved for treatment-resistant depression and certain other depressive conditions. It must be given in a certified healthcare setting with at least two hours of monitoring under a REMS program.
Can ketamine be prescribed through telehealth?
Under federal telemedicine flexibilities currently extended through December 31, 2026, clinicians can prescribe Schedule III drugs like ketamine without a prior in-person visit, subject to state law. That may change after 2026.
What are the main risks of at-home ketamine?
The FDA lists sedation, dissociation, increased blood pressure, slowed breathing, misuse, psychiatric effects and bladder problems, with added risk because no clinician is present to monitor.
What should I do if I have a bad reaction?
Call 911 for breathing problems, chest pain, severe confusion or loss of consciousness. Contact the prescribing program for other side effects, and report them to FDA MedWatch.
Sources
- FDA: FDA warns patients and health care providers about potential risks associated with compounded ketamine
- FDA: Spravato (esketamine) prescribing information
- Telehealth.org: DEA extends telehealth controlled-substance flexibilities through end of 2026
Medical guidance and labeling change. We link primary sources so you can check the current version yourself.